Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on UDG HEALTHCARE PLC. We currently have 25 research reports from 2 professional analysts.
|16Feb17 14:46||RNS||Director Declaration|
|07Feb17 15:45||RNS||Result of AGM|
|07Feb17 07:00||RNS||Board Appointment|
|07Feb17 07:00||RNS||1st Quarter Trading Update|
|06Feb17 12:17||RNS||Total Voting Rights|
|16Jan17 12:41||RNS||Holding(s) in Company|
|16Jan17 07:00||RNS||Notice of Q1 2017 Trading Update|
Frequency of research reports
Research reports on
UDG HEALTHCARE PLC
UDG HEALTHCARE PLC
N+1 Singer - UDG Healthcare - Forecasts updated to US$, investment case unch
16 Feb 17
Following the strong Q1 trading update, we have translated our forecasts into US$ to reflect the change in reporting currency. Our forecasts are pitched in the middle of the guidance of 13-16% CER EPS growth for FY17, although this reduces to +9.2% on a reported basis given FX headwinds. Beyond that, we believe 10% organic EPS growth is achievable given the improving mix towards higher value, higher margin activities in Ashfield Communications and Sharp Packaging. With substantial firepower still available for acquisitions, we continue to see significant potential upside. We stick with our Buy recommendation with a SOTP/DCF based Target Price of 755p.
N+1 Singer - UDG Healthcare - Strong Q1 update
07 Feb 17
A strong Q1 update reassures that UDG is capitalising on the twin investment theses of structural growth in the pharma outsourcing market and mix driven margin enhancement. The company is guiding to +13-16% EPS growth at CER, driven by good organic growth and recent acquisitions. The health net cash position also means UDG retains significant firepower for further deals, which should lead to further upgrade momentum in due course. We are reviewing our forecasts for the change in reporting currency and will reissue these shortly.
N+1 Singer - Morning Song 07-02-2017
07 Feb 17
Amino Technologies (AMO LN) Strong results drive further upgrades | Cambria Automobiles (CAMB LN) Board strengthened by appointment of 2 new NEDs | Mattioli Woods (MTW LN) Interims in line, strong revenue growth, acquisition of stake in Amati | Oxford Metrics - OMG (OMG LN) Introducing…Alloy | Speedy Hire (SDY LN) Trading update highlights further progress | UDG Healthcare (UDG LN) Strong Q1 update | Walker Greenbank (WGB LN) Underlying performance and growth starting to reveal themselves
N+1 Singer - Morning Song 24-11-2016
24 Nov 16
Abzena (ABZA LN) Positive Phase I/II data on Abzena inside programme OPN-305 | Actual Experience (ACT LN) 3-yr framework agreement with Accenture | CVS Group (CVSG LN) Strong AGM prompts double-digit upgrades | Euromoney Institutional Investor (ERM LN) No change to outlook | Futura Medical (FUM LN) Forecast update post equity capital raise | Marston’s (MARS LN) Solid finals and reassuring tenor | Sigma Capital Group (SGM LN) Milestone reached: 1000th PRS home completed and let | UDG Healthcare (UDG LN) In line prelims, outlook intact
Interim results – adhering to international growth strategy
23 Feb 17
Interim results showed a strong performance for Tristel, 6% ahead of its AGM statement on 12 December at which it indicated adjusted pre-tax profits to be no less than £1.6m. Revenues increased by 22% (16% at constant exchange rates – CER or 12% CER excluding the impact of the Australian acquisition) and adjusted pre-tax profits were up 15% to £1.71m. Despite the strong half, we leave our full-year forecasts unchanged, given FX uncertainty and a one-off stocking order in H1 from the NHS, although at current FX rates the risk to our forecasts is considered to be to the upside. However, we raise our target price by 10% to 165p to reflect the solid progress as well as rolling forward our multiples to calendar-adjusted 2017.
N+1 Singer - Morning Song 22-02-2017
22 Feb 17
CORETX (COR LN) Contract wins and new Lifestyle facility | Gooch & Housego (GHH LN) Solid Q1 trading plus earnings enhancing acquisition of StingRay Optics | NCC Group (NCC LN) Further issues in Assurance | PCI-PAL (PCIP LN) Strong H1 underpins positive outlook | UBM (UBM LN) Results | Verona Pharma (VRP LN) Phase IIa RPL554 add-on trial to tiotropium commenced
N+1 Singer - Morning Song 23-02-2017
23 Feb 17
Genus (GNS LN) Interim results: R&D step-up, disappointing ABS performance | Howden Joinery Group (HWDN LN) Prelims and net cash better than expected but conditions weaken | Oxford Pharmascience Group (OXP LN) Encouraging interim OXPzero™ Ibuprofen exploratory PK data | StatPro Group (SOG LN) Increased majority shareholding in Infovest Consulting | Wilmington Group (WIL LN) Interims slightly ahead, move to focus on 3 verticals
Consistently strong growth at a sensible price
24 Feb 17
In “Alice in Wonderland”, Lewis Carroll tells the story of a girl, who falls through a rabbit hole into a world populated by peculiar, anthropomorphic creatures. Here, Alice crosses swords with the Queen of Hearts, meets the Cheshire Cat and is invited to the "Mad Hatters” tea party, which she subsequently discovers is “stupid”.
N+1 Singer - Anpario - Feed for growth
24 Feb 17
Anpario’s natural animal feed additive product offering is well placed to benefit from the increasing demand for animal protein and tightening regulations around antibiotic use as growth promoters. The group is in a transition phase, building strong commercial relationships with end users, which we believe should benefit the margin. Anpario’s geographical diversity is a key positive and with a strong balance sheet there is potential for acquisitive as well as organic growth. We initiate coverage with a 354p Target Price and a Buy recommendation ahead of FY results on 8th March.
N+1 Singer - Morning Song 21-02-2017
21 Feb 17
Abzena (ABZA LN) Contract bookings strong; US costs higher than expected | City of London Investment Group (CLIG LN) Earnings and interim dividend in line, some modest growth in FuM | dotdigital Group (DOTD LN) Good H1; broadening avenues of growth | Grafenia (GRA LN) Weak print volumes | Vernalis (VER LN) Interims highlight increasing Tuzistra™ scrip volume